文献速递心律失常瓣膜病与结构性心脏病

肥厚型心肌病中心房颤动的临床特征与后果

Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
PubMed 文献 · Circulation · 2017-09-15

该研究回顾性分析了1558例肥厚型心肌病(HCM)患者,其中20%存在心房颤动(AF)。AF多为阵发性且症状明显,但较少进展为永久性;经治疗(抗心律失常药、消融或迷宫手术)后,AF患者疾病相关死亡率低,与无AF患者无差异;抗凝治疗可显著减少栓塞事件。

要点

  • HCM患者中AF患病率约20%,多数为阵发性,少数进展为永久性。
  • AF经治疗(药物、消融或迷宫手术)后,疾病相关死亡率与无AF者无差异。
  • 抗凝治疗可显著降低栓塞事件风险,支持放宽抗凝指征。

核心结论

  • AF在HCM中多为阵发性且症状明显,但当代治疗可有效控制,较少进展为永久性。
  • AF不是心力衰竭发病或心律失常性猝死的主要原因,治疗后可实现低疾病相关死亡率。
  • AF是HCM中不常见的直接死因,主要限于栓塞性卒中,支持降低抗凝启动阈值。

研究设计与样本

  • 回顾性队列研究,连续纳入1558例HCM患者,随访4.8±3.4年(2004-2014年)。

主要发现

  • 1558例中304例(20%)有AF发作,其中226例(74%)为症状性阵发性AF,78例(26%)发展为永久性AF。
  • AF患者中4%死于HCM相关原因(n=11),年死亡率0.7%;直接归因于AF(未预防性抗凝导致的血栓栓塞)的年死亡率为0.1%(n=2)。
  • 消融术后1年无AF复发率为44%,迷宫手术为75%(P<0.001)。
  • 抗凝预防组栓塞事件4/233(2%),未抗凝组9/66(14%)(P<0.001)。

关键数值与推荐

  • AF患者中91%存活,平均年龄62±13岁,89%为NYHA I或II级。
  • AF与年龄性别匹配的无AF HCM患者相比,结局指标无差异。

临床怎么用

  • 对HCM合并AF患者应积极考虑抗凝治疗以预防栓塞性卒中。
  • 阵发性AF症状明显者可选用抗心律失常药物(如胺碘酮、索他洛尔)或导管消融。
  • 合并外科肥厚型心肌病切除术时可行迷宫手术,其1年无复发率优于导管消融。

局限性

  • 单中心回顾性研究,可能存在选择偏倚。
  • 随访时间有限,长期结局未完全明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atrial fibrillation (AF), the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), is capable of producing symptoms that impact quality of life and is associated with risk for embolic stroke. However, the influence of AF on clinical course and outcome in HCM remains incompletely resolved. METHODS: Records of 1558 consecutive patients followed at the Tufts Medical Center Hypertrophic Cardiomyopathy Institute for 4.8±3.4 years (from 2004 to 2014) were accessed. RESULTS: Of the 1558 patients with HCM, 304 (20%) had episodes of AF, of which 226 (74%) were confined to symptomatic paroxysmal AF (average, 5±5; range, 1 to >20), whereas 78 (26%) developed permanent AF, preceded by 7±6 paroxysmal AF episodes. At last evaluation, 277 patients (91%) are alive at 62±13 years of age, including 89% in New York Heart Association class I or II. No difference was found in outcome measures for patients with AF and age- and sex-matched patients with HCM without AF. Four percent of patients with AF died of HCM-related causes (n=11), with annual mortality 0.7%; mortality directly attributable to AF (thromboembolism without prophylactic anticoagulation) was 0.1% per year (n=2 patients). Patients were treated with antiarrhythmic drugs (most commonly amiodarone [n=103] or sotalol [n=78]) and AF catheter ablation (n=49) or the Maze procedure at surgical myectomy (n=72). Freedom from AF recurrence at 1 year was 44% for ablation patients and 75% with the Maze procedure (P<0.001). Embolic events were less common with anticoagulation prophylaxis (4/233, 2%) than without (9/66, 14%) (P<0.001). CONCLUSIONS: Transient symptomatic episodes of AF, often responsible for impaired quality of life, are unpredictable in frequency and timing, but amenable to effective contemporary treatments, and infrequently progress to permanent AF. AF is not a major contributor to heart failure morbidity or a cause of arrhythmic sudden death; when treated, it is associated with low disease-related mortality, no different than for patients without AF. AF is an uncommon primary cause of death in HCM virtually limited to embolic stroke, supporting a low threshold for initiating anticoagulation therapy.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rowin EJ, Hausvater A, Link MS, et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017. PMID: 28916640. doi:10.1161/CIRCULATIONAHA.117.029267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。